- Home
- Publications
- Publication Search
- Publication Details
Title
Smoldering multiple myeloma current treatment algorithms
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 12, Issue 9, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-09-05
DOI
10.1038/s41408-022-00719-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
- (2022) Alissa Visram et al. LEUKEMIA
- Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
- (2021) Sigrun Thorsteinsdottir et al. BLOOD
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- (2020) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Smoldering Myeloma and the Art of War
- (2020) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
- (2019) Jens Hillengass et al. LANCET ONCOLOGY
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
- (2019) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement
- (2019) David Murray et al. Blood Cancer Journal
- Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
- (2018) Carlos Fernández de Larrea et al. LEUKEMIA
- Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
- (2018) Arjun Lakshman et al. LEUKEMIA
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
- (2018) Robert A. Kyle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
- (2018) Arjun Lakshman et al. Blood Cancer Journal
- Monoclonal Gammopathy–Associated Peripheral Neuropathy: Diagnosis and Management
- (2017) Hafsa M. Chaudhry et al. MAYO CLINIC PROCEEDINGS
- Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
- (2016) María-Victoria Mateos et al. LANCET ONCOLOGY
- Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
- (2016) P Ravi et al. Blood Cancer Journal
- Smoldering multiple myeloma
- (2015) S. V. Rajkumar et al. BLOOD
- 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
- (2015) E Zamagni et al. LEUKEMIA
- The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network
- (2014) N. W. C. J. van de Donk et al. HAEMATOLOGICA
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma
- (2014) M Merz et al. LEUKEMIA
- Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)
- (2013) M. V. Dhodapkar et al. BLOOD
- Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
- (2013) Kai Neben et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
- (2013) S V Rajkumar et al. LEUKEMIA
- Monoclonal Gammopathy–Associated Proliferative Glomerulonephritis
- (2013) Sanjeev Sethi et al. MAYO CLINIC PROCEEDINGS
- Treatment for High-Risk Smoldering Myeloma
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
- (2012) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
- (2012) G Bianchi et al. LEUKEMIA
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
- (2012) T E Witzig et al. LEUKEMIA
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- (2012) J T Larsen et al. LEUKEMIA
- Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
- (2011) Giovanni D'arena et al. LEUKEMIA & LYMPHOMA
- Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
- (2010) Martin Hjorth et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma
- (2010) Jens Hillengass et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
- (2010) Angela Dispenzieri et al. LANCET
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
- (2010) R A Kyle et al. LEUKEMIA
- A monoclonal gammopathy precedes multiple myeloma in most patients
- (2009) B. M. Weiss et al. BLOOD
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
- (2008) Pellegrino Musto et al. CANCER
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now